Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Plotnick

Cardiovascular Disease Towson, MD Medical Doctor

NPI 1356486039 CMS profile 152620

7505 Osler Dr, Towson, MD 21204

Open in the dashboard

General payments

$13,648

645 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Plotnick of Towson, MD is reported in the CMS Open Payments database as having received $13,648 across 645 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,971 79
2024 General $2,896 121
2023 General $2,826 140
2022 General $2,064 107
2021 General $744 42
2020 General $734 37
2019 General $2,412 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Plotnick
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Daniel Plotnick were reported at $1,971. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Daniel Plotnick Cardiovascular Disease median Middle half National median
2019 $2,412 $450 $127–$1,392 $163
2020 $734 $242 $77–$751 $114
2021 $744 $335 $101–$1,037 $132
2022 $2,064 $395 $121–$1,211 $149
2023 $2,826 $443 $136–$1,283 $160
2024 $2,896 $450 $136–$1,323 $164
2025 $1,971 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,406 94 payments
  2. E.R. Squibb & Sons, L.L.C. $1,216 86 payments
  3. Janssen Pharmaceuticals, Inc $993 65 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $970 40 payments
  5. Medtronic, Inc. $905 17 payments
  6. Edwards Lifesciences Corporation $784 11 payments
  7. Amgen Inc. $771 37 payments
  8. Novartis Pharmaceuticals Corporation $755 47 payments
  9. AstraZeneca Pharmaceuticals LP $698 40 payments
  10. Abbott Laboratories $486 6 payments
  11. Other $4,663 202 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,606 642 payments
  2. Education $23 2 payments
  3. Consulting Fee $19 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $975 73 payments
  2. XARELTO $974 64 payments
  3. ELIQUIS Cardiovascular $732 56 payments
  4. VYNDAQEL $660 37 payments
  5. Repatha $636 32 payments
  6. PAXLOVID $487 36 payments
  7. CAMZYOS $429 27 payments
  8. ENTRESTO $417 27 payments
  9. JARDIANCE $417 14 payments
  10. FARXIGA $405 22 payments
  11. Other $8,568 357 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

4,102

Median for Cardiology: 2,533

Drug cost

$1,077,765

Median for Cardiology: $485,213

Branded share of claims

27.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 497 $640,532
Xarelto Rivaroxaban Brand 99 $121,609
Entresto Sacubitril/Valsartan Brand 54 $72,343
Jardiance Empagliflozin Brand 49 $60,033
Repatha Sureclick Evolocumab Brand 34 $37,239
Brilinta Ticagrelor Brand 31 $31,547
Multaq Dronedarone Hcl Brand 20 $27,263
Praluent Pen Alirocumab Brand 21 $13,471
Repatha Syringe Evolocumab Brand 15 $12,844
Atorvastatin Calcium Generic 519 $7,449

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$222,215

Medicare's payments for the services billed

Medicare patients

1,693

Average age 77

Services billed

4,935

802 women, 891 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Arthritis 54%
Atrial fibrillation 45%
Heart failure 38%
Diabetes 37%
Chronic kidney disease 36%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $241
$241 49 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $108
  • PFIZER INC. $88
$196 497 —
XARELTO
  • Janssen Pharmaceuticals, Inc $176
$176 99 —
Repatha
  • Amgen Inc. $142
$142 49 —
Wegovy
  • Novo Nordisk Inc $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record